PMID- 35485164
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220716
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 4
DP  - 2022 Apr
TI  - LncRNA00978 contributes to growth and metastasis of hepatocellular carcinoma 
      cells via mediating microRNA-125b-5p/SOX12 pathway.
PG  - 11228-11239
LID - 10.1080/21655979.2022.2063648 [doi]
AB  - As a malignant tumor, HCC (hepatocellular carcinoma) is featured by a high 
      recurrence rate with a poor prognosis. Increasing evidence supports an important 
      role of lincRNAs in HCC. Here, the purpose of the study was to explore the 
      function of LINC00978 (long non-coding RNA00978) in HCC and the underlying 
      mechanisms. LINC00978 expression and its association with the progression of HCC 
      were analyzed using HCC TCGA datasets. LINC00978 expression in tissues was 
      measured using real-time PCR. Then, we knocked down LINC00978 in HCC cells to 
      explore its effect on cellular invasion, proliferation, and migration. Finally, 
      we investigated the potential molecular mechanism of LINC00978 by dual Luciferase 
      reporter assay, FISH (fluorescence in situ hybridization) and RIP (RNA 
      immunoprecipitation). LINC00978 expression was remarkably increased in HCC. A 
      high level of LINC00978 was associated with poor prognosis of HCC. Additionally, 
      LINC00978 silencing could repress the growth and metastasis of HCC cells. 
      Mechanistically, it was revealed that LINC00978 could sponge microRNA-125b-5p and 
      identified SOX12 (SRY-Box Transcription Factor 12) as a direct target gene of 
      microRNA-125b-5p. More importantly, the suppressed effect of LINC00978 silencing 
      on the metastasis and growth of HCC cells could be rescued by miR-125b-5p 
      inhibition and overexpressed SOX12. LINC00978/microRNA-125b-5p/SOX12 axis 
      promoted liver cancer migration, invasion, and proliferation, which could be used 
      as a possible therapeutic target for the treatment of hepatocellular carcinoma.
FAU - Cheng, Zhiqing
AU  - Cheng Z
AD  - Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Putian 
      University, Putian, Fujian, China.
FAU - Gong, Limei
AU  - Gong L
AD  - Department of General Medicine, Affiliated Hospital of Putian University, Putian, 
      Fujian, China.
FAU - Cai, Qinghe
AU  - Cai Q
AD  - Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Putian 
      University, Putian, Fujian, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MicroRNAs)
RN  - 0 (SOX12 protein, human)
RN  - 0 (SOXC Transcription Factors)
SB  - IM
MH  - *Carcinoma, Hepatocellular/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Liver Neoplasms/metabolism
MH  - *MicroRNAs/genetics/metabolism
MH  - SOXC Transcription Factors/genetics/metabolism
PMC - PMC9208515
OTO - NOTNLM
OT  - Invasion
OT  - LINC00978
OT  - SOX12
OT  - cell proliferation
OT  - hepatocellular carcinoma
OT  - microRNA-125b-5p
OT  - migration
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/04/30 06:00
MHDA- 2022/05/03 06:00
PMCR- 2022/04/29
CRDT- 2022/04/29 04:13
PHST- 2022/04/29 04:13 [entrez]
PHST- 2022/04/30 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2022/04/29 00:00 [pmc-release]
AID - 2063648 [pii]
AID - 10.1080/21655979.2022.2063648 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Apr;13(4):11228-11239. doi: 10.1080/21655979.2022.2063648.